{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:35:53Z","timestamp":1793352953788,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention for coronary bifurcation lesions remains uncertain. This meta-analysis focused on comparing ischemic and bleeding outcomes between short-term (\u22646 months) and long-term (&gt;6 months) DAPT in this high-risk subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included six studies comprising 12\u2005066 patients with bifurcation lesions treated with drug-eluting stents and either short- or long-term DAPT. Pooled relative risk (RR) and 95% confidence intervals (CI) were calculated for major adverse cardiovascular events (MACE), all-cause and cardiac mortality, myocardial infarction, stent thrombosis, stroke, bleeding, and target lesion revascularization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Short-term DAPT was associated with significantly higher risks of MACE (RR 1.79; 95% CI 1.05\u20133.07), all-cause mortality (RR: 2.78; 95% CI: 1.49\u20135.19), cardiac death (RR 2.29; 95% CI 1.34\u20133.91), and stent thrombosis (RR: 4.90; 95% CI: 2.78\u20138.66). Although the risks of myocardial infarction (RR: 1.75; 95% CI: 0.69\u20134.47), stroke (RR: 1.07; 95% CI: 0.61\u20131.67), bleeding (RR: 1.49; 95% CI: 0.24\u20139.48), and target lesion revascularization (RR: 1.35; 95% CI: 0.85\u20132.12) did not reach statistical significance, the effect estimates consistently favored long-term DAPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients undergoing percutaneous coronary intervention for bifurcation lesions, short-term DAPT was associated with significantly worse ischemic outcomes, including increased rates of MACE, death, and stent thrombosis. These findings support the use of extended DAPT duration as the preferred strategy in this anatomical subgroup, with treatment tailored according to individual bleeding risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mca.0000000000001648","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:04:03Z","timestamp":1777539843000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for bifurcation lesions: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"37","author":[{"given":"Ricardo F.O","family":"Suruagy-Motta","sequence":"first","affiliation":[{"name":"Department of Medicine, Cesmac University Center, Macei\u00f3, Alagoas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tirelli-Rocha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jundia\u00ed Medical School, Jundia\u00ed, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Guilherme Silva","family":"Almeida","sequence":"additional","affiliation":[{"name":"Department of Medicine, Catholic University of Bras\u00edlia, Bras\u00edlia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz P.","family":"Aguiar-Barros","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center, Macei\u00f3, Alagoas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Lima","family":"Mendes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Taubat\u00e9, Taubat\u00e9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Dexheimer da Silva","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalgi","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Louisiana State University Health, Shreveport, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cox-Alomar","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Henrique Magalh\u00e3es Craveiro","family":"de Melo","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, InCor, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro Martins","family":"Filho","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Santa Casa de Miseric\u00f3rdia, Macei\u00f3, Alagoas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Abizaid","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, InCor, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunna","family":"Pileggi","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, InCor, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"R1-20261030","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R2-20261030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"R3-20261030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention.","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"R4-20261030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"R5-20261030","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting.","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R6-20261030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10557-020-07009-6","article-title":"Tailoring dual antiplatelet therapy for the complex PCI patient: current status and perspectives.","volume":"34","author":"Benetou","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"R7-20261030","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI.","volume":"68","author":"Giustino","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R8-20261030","doi-asserted-by":"crossref","first-page":"e011536","DOI":"10.1161\/CIRCINTERVENTIONS.121.011536","article-title":"New insights into long- versus short-term dual antiplatelet therapy duration in patients after stenting for left main coronary artery disease: findings from a prospective observational study.","volume":"15","author":"Wang","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"R10-20261030","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R11-20261030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2013 a web and mobile app for systematic reviews.","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"R12-20261030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"R13-20261030","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R14-20261030","doi-asserted-by":"crossref","first-page":"133542","DOI":"10.1016\/j.ijcard.2025.133542","article-title":"Duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for bifurcation lesions: insights from the ULTRA-BIFURCAT registry.","volume":"438","author":"Nebiolo","year":"2025","journal-title":"Int J Cardiol"},{"key":"R15-20261030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40256-024-00657-1","article-title":"Impact of prolonged dual antiplatelet therapy after bifurcation percutaneous coronary intervention in patients with high ischemic risk.","volume":"24","author":"Khelimskii","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"R16-20261030","doi-asserted-by":"crossref","first-page":"e005849","DOI":"10.1161\/CIRCINTERVENTIONS.117.005849","article-title":"Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions: results from the coronary bifurcation stenting registry II.","volume":"11","author":"Jang","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"R17-20261030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.amjcard.2019.10.058","article-title":"Incidence of adverse events at 3 months versus at 12 months after dual antiplatelet therapy cessation in patients treated with thin stents with unprotected left main or coronary bifurcations.","volume":"125","author":"D\u2019Ascenzo","year":"2020","journal-title":"Am J Cardiol"},{"key":"R18-20261030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S0031-0808.22.04604-3","article-title":"Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the EuroBifurcation Club registry.","volume":"65","author":"Cirillo","year":"2023","journal-title":"Panminerva Med"},{"key":"R19-20261030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.amjcard.2019.10.046","article-title":"Long-term efficacy of extended dual antiplatelet therapy after left main coronary artery bifurcation stenting.","volume":"125","author":"Cho","year":"2020","journal-title":"Am J Cardiol"},{"key":"R20-20261030","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.3390\/jcm12185916","article-title":"Clinical outcomes following bifurcation techniques for percutaneous coronary intervention.","volume":"12","author":"Krittanawong","year":"2023","journal-title":"J Clin Med"},{"key":"R21-20261030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4244\/EIJ-D-20-00885","article-title":"Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions.","volume":"17","author":"Zimarino","year":"2021","journal-title":"EuroIntervention"},{"key":"R22-20261030","first-page":"1255","article-title":"Outcomes of the Tryton-dedicated bifurcation stent for the treatment of true coronary bifurcations: Individual-patient-data pooled analysis.","volume":"93","author":"Konigstein","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"R23-20261030","doi-asserted-by":"crossref","first-page":"e004497","DOI":"10.1161\/CIRCINTERVENTIONS.116.004497","article-title":"Clinical outcome of double kissing crush versus provisional stenting of coronary artery bifurcation lesions.","volume":"10","author":"Chen","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"R24-20261030","first-page":"168","article-title":"Efficacy and safety of short-term (\u22646 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials.","volume":"17","author":"He","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"R25-20261030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/fca-2017-0068","article-title":"Treatment of coronary bifurcation lesions: current knowledge and future perspectives.","volume":"14","author":"Elwany","year":"2018","journal-title":"Future Cardiol"},{"key":"R26-20261030","first-page":"182","article-title":"New insights into intravascular imaging of coronary bifurcation lesions and left main stenosis: what have we accomplished?","volume":"2","author":"Leesar","year":"2022","journal-title":"Cardiol Discov"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:02:18Z","timestamp":1793350938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001648","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2026-02-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}